LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, will

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 -   LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc.

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter - The Board of Directors has established an Office of the CEO to manage the company through the transition, with Mike Bonney , Executive Chair, to lead the office and Alison Lawton to serve as

LEXINGTON, Mass. , June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that in light of the COVID-19 pandemic, its 2020

LEXINGTON, Mass. , June 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton , President and Chief

LEXINGTON, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering

LEXINGTON, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and

- Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 - - Expanding Work in Immune-Mediated and Inflammatory Diseases; Data from New Clinical Study in Ulcerative Colitis Expected in Mid-2021 - - Conference Call Scheduled for 8:30 a.m.

- Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 -             - Second Clinical Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis - LEXINGTON, Mass. , May 14, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc.